We've made it easier for you to connect! Fill out your NEW profile.
FDA Approves Enhertu for Unresectable or Metastatic HER2-Low BC

moderators
Posts: 9,091
FDA Approves Enhertu for Unresectable or Metastatic HER2-Low Breast Cancer
Aug 5, 2022
On Aug. 5, 2022, the U.S. Food and Drug Administration approved Enhertu to treat unresectable or metastatic HER2-low breast cancer. Read more...
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your NEW profile.